A Double-Blind Study of E5555 in Japanese Subjects With Coronary Artery Disease.
Phase of Trial: Phase II
Latest Information Update: 10 May 2013
At a glance
- Drugs Atopaxar (Primary)
- Indications Coronary artery disease; Embolism and thrombosis
- Focus Adverse reactions; Biomarker; Pharmacodynamics
- Acronyms J-LANCELOT
- Sponsors Eisai Co Ltd
- 27 Mar 2012 Biomarker results presented at the 61st Annual Scientific Session of the American College of Cardiology.
- 30 Aug 2010 Results have been published in the European Heart Journal.
- 30 Aug 2010 Results have been presented at ESC Congress 2010: Annual Congress of the European Society of Cardiology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History